In recent years, stem cell biology research has advanced, and cancer stem cells (CSCs) were detected not only in hematological malignancies but also in solid tumors [1] [2] [3] . CSCs, also called side populations, are a distinct subpopulation in the solid tumors. These cells maintain tumor mass by giving rise to new cancer cells while preserving their anaplastic abilities by self-renewal [4] . Most CSCs show resistance to conventional anticancer strategies such as chemotherapeutic agents and radiation therapies [5] . Therefore, this cell population has been considered as the origin of disease recurrence and metastasis in the long course of cancer progression. The efficient depletion of CSCs from tumors can be achieved by targeting CSC-specific regulatory factors. The development of therapeutic drugs targeting such factors can lead to the radical cure of cancers. Up to now, the analysis of CSC characterization has been restricted and the crucial factors regulating both normal and cancer stem cell processes have not been explored, on account of the complexity in propagating CSCs in vitro [6] . Recently, several research groups attempted to establish new CSC models [7, 8] .
Separation and purification of cancer stem-like cells from some cancer cell lines is the most common method. It is well established that CSC-like cells can be augmented by collecting cells expressing surrogate CSC markers including CD133, CD44 and aldehyde dehydrogenase (ALDH) [2, 3, 9, 10] . An alternative approach for the enrichment of CSCs utilized transformed cancer cell lines that were forced to undergo tumor sphere formation or epithelial-to-mesenchymal transition (EMT) [11] [12] [13] . CSCs that were derived from cancer cell lines expressed surrogate CSC markers and displayed putative tumorigenic properties in vivo. Collectively, these findings highlight the potential suitability of cancer cell line models for the discovery of compounds that selectively target CSCs.
Despite the advantages of CSCs models, the extensive genetic variability associated with chromosomal instabilities in over-passaged cancer cell lines remains a limitation that prevents consistent findings in large-scale drug screening assays. Furthermore, the enrichment of cancer stem-like cells
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from cancer cell lines using tumor sphere cultures is not always effective [14] . The continued improvement of cancer cell line models that possess the hallmarks of CSCs should encourage the development of CSC research. The ideal CSCs model uses genetically "homogeneous" human CSCs with negligible accumulation of genetic mutations and limited variation between cell clones to ensure reproducibility and fidelity in large-scale drug screening assays. Although it is also important to establish large-scale cultures that can be easily and cost-effectively performed, the identification of a human cancer stem cell line for this purpose has not yet been established.
The activation of oncogenes, the inactivation of tumor To identify compounds with a low cytotoxicity and that abrogate CSC traits such as cellular stemness, self renewal and tumorigenicity were assayed as indicated.
suppressor genes, the loss of signals for apoptosis, and senescence are crucial events in carcinogenesis and cancer stem-genesis [15] . We focused on the inactivation of tumor suppressors genes in the establishment of CSC model because these genes are consistently mutated in many human malignancies. Normal human somatic cells such as primary fibroblasts tend to undergo cellular senescence rather than transformation by oncogenic H-ras transduction. Normal cells have a mechanism to prevent malignant transformation via the induction of cellular senescence called oncogene-induced senescence (OIS). In OIS, the tumor suppressor genes p53, p21, and p16 play a critical role as gate-keepers to prevent carcinogenesis [16] . It is notable that a phenomenon similar to OIS also occurs during the generation of iPS cells. In fact, a majority of cells undergo senescence during the course of nuclear reprogramming and this can be defined as reprogramming-induced senescence (RIS) [17] . This phenomenon can also be achieved by tumor suppressors p53, p21 and p16. In fact, selective suppression of p53, p21 or p16 significantly increased the efficiency of iPS cell generation [18, 19] ; however, many malignantly transformed iPS cells also developed [20] . These malignantly transformed iPS cells formed malignant tumors with the capacity to differentiate into all three germ layers following transplantation into immunosuppressed mice. Thus, it is possible to generate transformed iPS cells that resemble CSCs from somatic cells that avoided RIS via nuclear reprogramming. These cells likely acquire both stemness and malignant properties simultaneously upon reprogramming.
MCF-10A cells are spontaneously immortalized mammary epithelial cells with a variety of cell phenotypes that mimic normal mammary epithelial cells in culture [21, 22] . MCF-10A cells have a near-diploid karyotype with minor genetic modifications including a loss of the p16 locus. We decided to use MCF-10A cells in the CSC model because of their relatively uniform genetic variability [23] . The reprogramming transcription factors Oct3/4, Sox2, Klf4, and c-Myc were transduced into MCF-10A cells for oncogenic reprogramming [23] , and we obtained iPS-like (iPSL) colonies. Transformed iPS colonies were selected based on their morphology and strong alkaline phosphatase staining, and subsequently subjected to partial differentiation into CSCs in vitro. The cells were then optimized by culturing in regular cell culture medium containing fetal bovine serum (FBS). We finally established four clones of induced CSC-like (iCSCL) cells termed iCSCL-10A ( Figure 1A ) [24] .
The iCSCL-10A cells expressed the CSCs markers CD44, SOX2 and ALDH1A1 had a higher sphere forming ability than conventional cancer cell lines. Furthermore, only several hundred iCSCL-10A cells were required for the formation of hierarchically-organized tumors in immunosuppressed mice in a short period (~10 days). These cells were resistant to anticancer agents that typically target cancer cells. iCSCL-10A cells were successfully cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS, thus highlighting the ease of manipulation and amenability of our model to large-sized drug screening. Hence, our model provides a beneficial tool for the analysis of CSC properties and drug discovery specifically targeting CSCs.
We utilized iCSCL-10A cells for our high-throughput drug screening assay and monitor phenotypic traits of CSCs in the presence of various compounds ( Figure 1B ) [25] . The activity and selectivity of the therapeutic agents were assessed using three distinct assays: 1) cell viability assay for cell toxicity, 2) alkaline phosphatase (ALP) assay for cellular stemness, and 3) tumor sphere forming assay for self-renewal. The assays were designed using a 96-well platform and evaluated 73 organic compounds in parallel. Interestingly, we found that an Ayurvedic medicine constituent, Withaferin A (WA), drastically reduced the number of ALP-positive cells with negligible cytotoxicity at 1 μM as evidenced by a cell viability greater than 80% [26] . WA significantly prohibited tumor sphere formation highlighting its ability to spoil the self-renewal ability of iCSCL-10A cells. WA reduced the expression of stem cell and EMT markers. Notably, WA blocked cell migration and invasion of iCSCL-10A cells. Moreover, pre-treatment with WA almost completely suppressed the tumorigenicity of iCSCL-10A cells. Treatment with WA induced the tumor suppressor p21Cip1 which abolished the CSC characteristics of iCSCL-10A cells via the induction of cellular senescence. In addition, the persistent activation of mitogenic pathways such as mTOR and/or MAPK/MEK in iCSCL-10A facilitated cellular senescence via geroconversion [27] . Further studies are needed to determine whether long-term treatment with WA will have profound effects on CSCs in vivo while not being harmful to normal stem cells. However, our study demonstrated the applicability of our CSC model for the identification and characterization of novel therapeutic agents that target CSCs based on their phenotypic properties. Our CSC model improves the ease of characterization of CSCs by allowing the examination of CSC-specific functions, including self-renewal and tumor-initiating properties.
In summary, we have developed a method for the oncogenic reprogramming of human mammary epithelial cells that is a potentially valuable tool for the study of CSCs. These cells are potentially useful for high-throughput screening to identify selective inhibitor of CSCs. Our approach provides a simple, easy, cost-effective, and highly reproducible assay system that is applicable to large-scale drug screening assays. This current approach holds great promise for the future development of novel anti-CSC drugs with the aim of completely curing of cancer.
